Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

2.4K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

866
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
866
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

423
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

901
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
901
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

616
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
616

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same journal

Erosion of Professional Medical Standards by the Supreme Court.

JAMA·2026
Same journal

Tumor Debulking Plus Chemotherapy in Multiorgan Metastatic Colorectal Cancer-Reply.

JAMA·2026
Same journal

Choosing Distance: Medical Professionalism and Poetry.

JAMA·2026
Same journal

Tumor Debulking Plus Chemotherapy in Multiorgan Metastatic Colorectal Cancer.

JAMA·2026
Same journal

Human Papillomavirus Screening and Self-Collected Vaginal Samples.

JAMA·2026
Same journal

Distance Learning.

JAMA·2026

相关实验视频

Updated: Apr 14, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

高血压患者的重大心血管事件随机分配给多克萨佐辛与甲基:抗高血压和降脂治疗以预防心脏病发作试验 (ALLHAT). 艾尔哈特协作研究小组 (ALLHAT) 合作研究小组

    JAMA
    |May 2, 2000
    PubMed
    概括

    作为利尿剂的甲基显示出与阿尔法阻断剂多克萨佐辛相似的冠状动脉心脏病事件风险. 然而,在高血压患者中,甲显著降低了整体心血管疾病事件,特别是充血性心力衰竭.

    科学领域:

    • 心脏病学 心脏病学
    • 药理学 药理学 是一个学科.
    • 临床试验 临床试验

    背景情况:

    • 高血压显著增加了患病和死亡的风险.
    • 利尿剂和β抑制剂已被证明可以降低与高血压相关的风险.
    • 新型抗高血压药物在降低心血管疾病 (CVD) 发病率方面的有效性仍然不确定.

    研究的目的:

    • 为了比较阿尔法阻断剂多克萨佐辛和利尿剂甲对高血压患者心血管疾病发病率的影响.
    • 这是一项更大规模的研究的一部分,评估了四种抗高血压药物类别:chlorthalidone,doxazosin,amlodipine和lisinopril.

    主要方法:

    • 一个随机,双盲,主动受控试验 (抗高血压和降脂治疗以预防心脏病发作试验).
    • 24,335名55岁以上的高血压患者具有心脏病风险因素,被随机分配给chlorthalidone (n=15,268) 或doxazosin (n=9067).
    • 该研究因中期分析而提前中止,结果反映了直到1999年12月的后续工作.

    主要成果:

    • 在致死性冠状动脉心脏病 (CHD) 或非致死性心肌梗塞 (MI) 的初级结局中,多克萨佐辛和甲之间没有显著差异 (RR,1.03;95% CI,0.90-1.17).
    • 与chlorthalidone相比,多克萨佐辛的中风风险 (RR,1.19;95% CI,1.01-1.40) 和结合心血管疾病事件 (RR,1.25;95% CI,1.17-1.33) 的风险更高.

    更多相关视频

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
    05:57

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

    Published on: May 17, 2024

    1.3K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.2K

    相关实验视频

    Last Updated: Apr 14, 2026

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    9.0K
    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
    05:57

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

    Published on: May 17, 2024

    1.3K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.2K
  • 与甲相比,多克萨佐辛 (RR,2.04;95% CI,1.79-2.32) 的结合性心力衰竭 (CHF) 风险翻了一番.

    • 结论:

    • 甲基在预防心血管疾病死亡和非致命性心脏病发作方面表现出与多克萨佐辛相当的疗效.
    • 甲显著降低了高风险高血压患者联合心血管疾病事件的风险,特别是心血管疾病风险.
    • 这些发现表明,在高风险人群中,甲可能是比多克萨佐辛更好的选择,用于管理高血压.